Interplay Between State Boards of Pharmacy and FDA in Compounding Oversight The intricate regulatory landscape for compounding oversight involves various stakeholders, primarily the state boards of pharmacy and the U.S. Food and Drug Administration (FDA). This article elucidates the workings, responsibilities, and regulatory challenges posed by the interaction between these entities in the context of OTC monograph reform, 503A and 503B facilities, and the implications of the CARES Act. The focus is on aiding pharma professionals, regulatory affairs specialists, and clinical operations teams in grasping the fundamentals and nuances of FDA regulations and guidance affecting compounding practices. Understanding the Regulatory…

Internal audits focused on compounding and OTC compliance in health systems Internal Audits Focused on Compounding and OTC Compliance in Health Systems Introduction to Internal Audits in Health Systems Internal audits are critical components of compliance programs in health systems, especially in the realm of pharmaceutical and healthcare operations. These audits serve to ensure adherence to regulatory standards, including those set forth by the US Food and Drug Administration (FDA). In the context of OTC (Over-the-Counter) monograph reform and compounding regulations, internal audits not only evaluate compliance with existing laws but also prepare organizations for upcoming changes, particularly in light…

Vendor and Pharmacist Training on 503A, 503B, and OTC Reform Requirements The FDA’s evolving regulatory landscape surrounding OTC monograph reform, 503A compounding, and 503B outsourcing facilities presents significant implications for pharmacists and vendors in the pharmaceutical industry. Understanding these regulations is vital for ensuring compliance and effectively navigating the complexities of drug approval and manufacturing. This tutorial provides a comprehensive overview of regulatory requirements and guidelines as per the recent reforms introduced by the CARES Act and the implications of the Drug Listing and labeling requirements. Understanding OTC Monograph Reform The OTC Monograph Reform, formalized under the CARES Act, instituted…

Compounding of Biologics, Insulin and Other High Risk Products Regulatory Views Compounding of Biologics, Insulin and Other High Risk Products Regulatory Views Understanding the Regulatory Landscape of Compounding The landscape of pharmaceutical compounding, especially of biologics, insulin, and other high-risk products, demands meticulous compliance with FDA regulations and guidance. The push of the CARES Act has reshaped this environment, enhancing scrutiny and offering new frameworks for compounding activities. This tutorial provides a comprehensive overview of the regulatory views concerning compounding practices within the U.S., with relevant considerations from the UK and EU where applicable. Within this tutorial, we’ll explore the…

Supply Chain and Quality Risks Unique to Compounded Sterile Preparations Compounded sterile preparations (CSPs) represent a crucial component of patient care, ensuring that individuals receive tailored therapies not available through traditional pharmaceutical channels. However, these preparations pose unique risks associated with supply chain management and quality assurance. This article provides a step-by-step guide for pharmaceutical professionals, clinical operations, regulatory affairs, and medical affairs personnel to navigate the regulatory landscape outlined by the FDA in adherence to 21 CFR standards, with a focus on the reform of OTC monographs, 503A compounding, and 503B outsourcing facilities. Understanding Compounded Sterile Preparations Compounded sterile…

Future policy directions for compounding, monograph innovation and safety Future Policy Directions for Compounding, Monograph Innovation and Safety Introduction to OTC Monograph Reform and Compounding Regulations The landscape of over-the-counter (OTC) pharmaceuticals is evolving rapidly due to regulatory reforms aimed at improving safety, efficacy, and market access. In the United States, the OTC Monograph Reform is pivotal in reshaping how products are developed, approved, and brought to market. Professionals in the pharmaceutical and clinical operations space must familiarize themselves with the implications of this reform, especially concerning Compounding facilities, including 503A and 503B establishments. In this tutorial, we will explore…

Inspection Readiness Checklists for 503B Facilities and OTC Monograph Sites In the dynamic landscape of pharmaceutical regulation, compliance with US FDA guidelines is critical for ensuring the quality and safety of products. This article serves as a comprehensive tutorial on inspection readiness checklists specifically for 503B outsourcing facilities and OTC monograph sites in the context of the recent OTC monograph reform. As regulatory expectations grow increasingly complex, the primary focus will be on providing practical guidance tailored for pharma professionals, clinical operations, regulatory affairs, and medical affairs specialists. Understanding the Regulatory Framework for 503B Facilities The Drug Quality and Security…

Global perspective on compounding versus licensed manufacturing standards Understanding Compounding versus Licensed Manufacturing Standards in the Pharmaceutical Industry Introduction to Compounding and Licensed Manufacturing The pharmaceutical landscape encompasses a variety of processes for drug production, notably compounding and licensed manufacturing. Compounding, a practice primarily defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, allows pharmacists and physicians to prepare personalized medications for patients. In contrast, licensed manufacturing involves the large-scale production of commercially available drugs regulated under 21 CFR Parts 210 and 211. It is essential for pharmaceutical professionals to understand the regulatory distinctions between these two…

Digital tools to track monograph changes, OMORs and compounding guidance Digital Tools to Track Monograph Changes, OMORs, and Compounding Guidance Introduction to OTC Monograph Reform The FDA’s Office of Nonprescription Products oversees the regulation of over-the-counter (OTC) medications. The OTC monograph reform is part of the broader efforts to enhance the regulation and approval process for these products. Implemented under the CARES Act, this reform establishes an efficient and modernized process for the development and review of OTC monographs. Understanding the implications of these changes is critical for pharmaceutical professionals involved in regulatory affairs and product development. The central features…

Risk Management and Communication for Recalls from 503B Outsourcing Facilities The rise of compounding pharmacies and outsourcing facilities has shifted the landscape of drug manufacturing and distribution. Understanding the risk management strategies and communication protocols for recalls is crucial for professionals in the pharmaceutical arena, particularly those associated with 503B outsourcing facilities. This guide aims to provide a comprehensive overview of the relevant regulations, best practices, and steps to ensure compliance under the regulatory framework established by the FDA. Understanding 503B Outsourcing Facilities Under the Drug Quality and Security Act (DQSA) of 2013, the FDA established the regulatory structure for…